ArchiveNovember 2009

2009 European Charcot Foundation Symposium

The 2009 European Charcot Foundation Symposium gathered many world opinion leaders in MS in Lisbon for a 3 day meeting to discuss “A new treatment era in multiple sclerosis: options, challenges and risks”. Prof Lassmann. In brain lesions in secondary progressive MS (SPMS), about 65% of cells are clonally expanded MHC class I CD8+ T cells that seem to escape apoptosis and outnumber CD4+T cells...

CCSVI

Recently, evidence has emerged – and widely publicised – that a condition called “chronic cerebro-spinal venous insufficiency (CCSVI)” may play a role in the pathogenesis of multiple sclerosis (MS). Paolo Zamboni, professor and director of the Vascular Diseases Centre at the University of Ferrara (Italy), and co-workers detected anomalies of venous drainage from the brain and spinal cord in all...

Immunology highlights ECTRIMS 2009

The highlight of ECTRIMs was the talk by the famous pathologist Prof John Prineas (Sydney, Australia), who was awarded the prestigious Charcot Prize for his unique contributions to the pathology of MS. The prize is named after the famous French neurologist also called “the Napoleon of the neuroses”. He was the first to describe multiple sclerosis as a distinct disease entity. This talk...

Label change for Natalizumab

09 November 2009 Elan & Biogen-Idec have made changes to the label on Natalizumab to reflect the increased risk of PML over a longer period of time. They are updating the label following consultation with the FDA; “risk of developing progressive multifocal leukoencephalopathy increases with longer treatment duration, and for patients treated for 24 to 36 months is generally similar to the...

Translate

Categories

Recent Posts

Recent Comments

Archives